Published January 1, 2021
| Version v1
Journal article
Open
Evaluation of potential tumor markers that may predict neoadjuvant treatment efficiency in rectal cancer
Creators
- 1. Univ Hlth Sci, Tepecik Training & Res Hosp, Dept Med Biochem, Gaziler St,468, TR-35180 Izmir, Turkey
- 2. Dokuz Eylul Univ, Inst Hlth Sci, Dept Mol Med, Izmir, Turkey
- 3. Univ Hlth Sci, Tepecik Training & Res Hosp, Gen Surg Clin, Izmir, Turkey
- 4. Univ Hlth Sci, Tepecik Training & Res Hosp, Med Pathol Clin, Izmir, Turkey
- 5. Univ Hlth Sci, Tepecik Training & Res Hosp, Radiol Clin, Izmir, Turkey
- 6. Univ Hlth Sci, Tepecik Training & Res Hosp, Oncol Clin, Izmir, Turkey
- 7. Katip Celebi Univ, Fac Med, Dept Biostat, Izmir, Turkey
Description
Objectives: The recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1 alpha (HIF-1 alpha) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC).
Files
bib-ac5d5eef-9483-4386-9e51-b9bf50806926.txt
Files
(322 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:746770f9982495d04496be2a63a0026f
|
322 Bytes | Preview Download |